logo

For the Inventor, By the Inventor

Tainan, Taiwan

Scinopharm Taiwan, Ltd.

USPTO Granted Patents = 77

% Expired Patents = 53.2



Trademarks = 5

Forward Citations = 87

Loading Chart...
Loading Chart...

111 inventors (with patents filed for the assignee):

goldMedal Julian Paul Henschke (19 out of 23 patents)

silverMedal Tsung-Yu Hsiao (13 out of 15 patents)

bronzeMedal Tsung-Cheng Hu (10 out of 10 patents)

4.  Yung-Fa Chen (10 out of 14 patents)

5.  Xiaoheng Zhang (7 out of 9 patents)

6.  Yuan-Xiu Liao (5 out of 7 patents)

7.  Wen-Wei Lin (5 out of 7 patents)

8.  YuanChang Huang (5 out of 5 patents)

9.  Shu-Ping Chen (5 out of 8 patents)

10.  George Schloemer (5 out of 10 patents)

11.  Hardy W Chan (4 out of 5 patents)

12.  Yung-Hung Chang (4 out of 4 patents)

13.  Ming-Chih Wu (4 out of 4 patents)

14.  Wei-Shuo Lo (4 out of 4 patents)

15.  Ping-Yu Wu (4 out of 4 patents)


Core Competencies:
Drug Purification
Synthesis Methods
Crystalline Forms
Mesoporous Silica
SGLT2 Inhibitors
Prostaglandin Analogs
Antibody-Liposome Complexes
High-Throughput Screening
Polymorphism
Chiral Catalysts
Nucleosides
Peptide Purification

77 patents:

1. 12643911 - Process for preparing Relugolix and intermediates thereof (2026-06-02),
2. 12274688 - Drug-loaded mesoporous silica nanoparticle for prevention and treatment of brain cancers or brain metastases (2025-04-14),
3. 12269844 - Process for purifying semaglutide and liraglutide (2025-04-08),
4. 11780824 - Process for preparing osimertinib or a salt thereof (2023-10-10),
5. 11459354 - Process for purifying liraglutide (2022-10-04),
6. 11384054 - Crystalline form of ivacaftor and a process for preparing the same (2022-07-12),
7. 11339131 - Process for preparing elagolix sodium and intermediates thereof (2022-05-24),
8. 10919905 - Polymorphism for irinotecan free base (2021-02-16),
9. 10703728 - Crystalline form of olaparib and a process for preparing the same (2020-07-07),
10. 10435395 - Crystal forms of lifitegrast (2019-10-08),
11. 10428052 - Process for preparing lifitegrast and intermediates thereof (2019-10-01),
12. 10385142 - Method for preparing sugammadex sodium (2019-08-20),
13. 10138215 - Process for preparing ataluren and its intermediates (2018-11-27),
14. 10138211 - Crystalline forms of olaparib and manufacturing processes therefor (2018-11-27),
15. 10118937 - Process for preparing ixazomib citrate and intermediates therefor (2018-11-06),
Company Overview
Scinopharm Taiwan, Ltd. is a prominent player in the pharmaceutical sector, specializing in advanced drug purification and synthesis methods. The company focuses on developing innovative crystalline forms and mesoporous silica technologies, enhancing the efficacy and delivery of therapeutic agents. With expertise in SGLT2 inhibitors, prostaglandin analogs, and antibody-liposome complexes, Scinopharm is committed to advancing pharmaceutical processes. Headquartered in Tainan, Taiwan, the organization plays a vital role in the global pharmaceutical landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

77 Patents

#16 in Tainan

#291 in Taiwan

#9,777 in the World

Tainan, TW
Tainan, Taiwan

Scinopharm Taiwan, Ltd.

Forward Citations = 87

111 inventors:

goldMedal Julian Paul Henschke (19 out of 23 patents)

silverMedal Tsung-Yu Hsiao (13 out of 15 patents)

bronzeMedal Tsung-Cheng Hu (10 out of 10 patents)

4.  Yung-Fa Chen (10 out of 14 patents)

5.  Xiaoheng Zhang (7 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Scinopharm Taiwan, Ltd.. Retrieved from https://idiyas.com/company/scinopharm-taiwan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…